[1]徐蕾 马晓燕.基于“肠-肾轴”理论治疗慢性肾脏病研究进展[J].陕西中医药大学学报,2022,(03):114-119.[doi:10.13424/j.cnki.jsctcm.2022.03.026]
 XU Lei MA Xiaoyan.Research Progress in Treatment of Chronic Kidney Disease Based on “Intestine-Kidney Axis” Theory[J].Journal of Shaanxi University of Traditional Chinese Medicine,2022,(03):114-119.[doi:10.13424/j.cnki.jsctcm.2022.03.026]
点击复制

基于“肠-肾轴”理论治疗慢性肾脏病研究进展
分享到:

《陕西中医药大学学报》[ISSN:2096-1340/CN:61-1501/R]

卷:
期数:
2022年03期
页码:
114-119
栏目:
综述
出版日期:
2022-05-26

文章信息/Info

Title:
Research Progress in Treatment of Chronic Kidney Disease Based on “Intestine-Kidney Axis” Theory
文章编号:
2096-1340(2022)03-0114-06
作者:
徐蕾1 马晓燕2
1.辽宁中医药大学,辽宁 沈阳 110847;
2.辽宁中医药大学附属医院,辽宁 沈阳 110032
Author(s):
XU Lei1 MA Xiaoyan2
1.Liaoning University of Traditional Chinese Medicine,Shenyang 110847,China;
2.Affiliated Hospital of Liaoning University of Traditional Chinese Medicine,Shenyang 110032,China
关键词:
关键词:肠-肾轴慢性肾脏病肠道微生态肠道菌群
Keywords:
Key words: Intestine-kidney axisChronic kidney diseaseIntestinal microecologyIntestinal flora
分类号:
R256.5
DOI:
10.13424/j.cnki.jsctcm.2022.03.026
文献标志码:
A
摘要:
摘 要:慢性肾脏病(chronic kidney disease,CKD)患病率不断增加,日益成为全球性公共卫生问题。随着肠道微生态与CKD相互影响的“肠-肾轴”理论逐渐成为研究热点,基于“肠-肾轴”理论的治疗方法应运而生,改变饮食结构、补充益生菌益生元、口服肠道吸附剂、缓泻剂以及中医从脾治肾、通腑泄浊法均对CKD具有一定的疗效。
Abstract:
Abstract: The prevalence of chronic kidney disease (CKD) is increasing and has increasingly become a global public health problem.With the interaction between intestinal microecology and CKD,the “Intestine-kidney axis” theory has gradually become a research hotspot.The treatment methods based on the “Intestine-kidney axis” theory came into being.Changing the diet structure,supplementing probiotics and prebiotics,oral intestinal adsorbents,laxatives and traditional Chinese medicine treating the kidney from the spleen and dredging the Fu organs and relieving turbidity have certain curative effects on CKD.

参考文献/References:

[1]上海慢性肾脏病早发现及规范化诊治与示范项目专家组,高翔,梅长林.慢性肾脏病筛查诊断及防治指南[J].中国实用内科杂志,2017,37(1):28-34.
[2]Ritz E.Intestinal-renal syndrome:mirage or reality?[J].Blood Purification,2011,31(1-3):70-76.
[3]Meijers BKI,Evenepoel P.The gut-kidney axis:indoxyl sulfate,p-cresyl sulfate and CKD progression[J].Nephrology Dialysis Transplantation,2011,26(3):759-761.
[4]Pahl MV,Vaziri ND.The chronic kidney disease-colonic axis[J].Seminars in Dialysis,2015,28(5):459-463.
[5]王娴娴,沈沛成.“肠-肾轴”与慢性肾脏病[J].安徽中医药大学学报,2018,37(6):4-7.
[6]蒋红利.慢性肾脏病的肠道微生态变化[J].肾脏病与透析肾移植杂志,2017,26(2):155-156.
[7]谢珊.肠道菌群结构变化与慢性肾功能衰竭发展关系的研究[D].广州:南方医科大学,2014.
[8]Vaziri ND,Yuan J,Norris K.Role of urea in intestinal barrier dysfunction and disruption of epithelial tight junction in chronic kidney disease[J].American Journal of Nephrology,2013,37(1):1-6.
[9]王尊松,崔美玉,唐利军,等.尿毒症患者肠黏膜免疫屏障功能与容量负荷和营养状况的关系[J].山东医药,2014,54(41):3-5.
[10]梁玉婷,胡丽萍,陈伶俐,等.尿毒症血液透析患者胃肠道症状发生情况及其对生活质量的影响[J].护理学报,2014,21(12):1-5.
[11]焦书沛,姜晨.“肠-肾轴”理论研究现状及分析[J].中国中西医结合肾病杂志,2017,18(7):656-658.
[12]樊均明,马欣,文集.肠道菌群的微生态改变与慢性肾脏疾病[J].中国中西医结合肾病杂志,2013,14(12):1035-1037.
[13]袁伟杰,王玲.肠道微生态与肾脏疾病[J].肾脏病与透析肾移植杂志,2017,26(2):153-154.
[14]许英,王姝,彭俊华.肠道菌群与机体疾病及慢性肾脏疾病的研究进展[J].国际检验医学杂志,2018,39(14):1759-1762.
[15]Armani RG,Ramezani A,Yasir A,et al.Gut microbiome in chronic kidney disease[J].Current Hypertension Reports,2017,19(4):29.
[16]Richards JL,Yap YA,McLeod KH,et al.Dietary metabolites and the gut microbiota:an alternative approach to control inflammatory and autoimmune diseases[J].Clinical & Translational Immunology,2016,5(5):e82.
[17]韩文贝,刘莹露,万毅刚,等.慢性肾脏病肠道菌群失调的病理机制、治疗策略及中药的干预作用[J].中国中药杂志,2017,42(13):2425-2432.
[18]王江丽,张文贤,赵嘉懿,等.肠道微生态与慢性肾脏病[J].临床荟萃,2017,32(6):537-540,544.
[19]Rossi UG,Petrocelli F,Seitun S,et al.Nonocclusive mesenteric ischemia in a dialysis patient with extensive vascular calcification[J].American Journal of Kidney Diseases,2012,60(5):843-846.
[20]Felizardo RJF,Castoldi A,Andrade-Oliveira V,et al.The microbiota and chronic kidney diseases:a double-edged sword[J].Clinical & Translational Immunology,2016,5(6):86.
[21]Mair RD,Sirich TL,Plummer NS,et al.Characteristics of colon-derived uremic solutes[J].Clinical Journal of the American Society of Nephrology:CJASN,2018,13(9):1398-1404.
[22]Evenepoel P,Poesen R,Meijers B.The gut-kidney axis[J].Pediatric Nephrology,2017,32(11):2005-2014.
[23]Black AP,Cardozo LFMF,Mafra D.Effects of uremic toxins from the gut microbiota on bone:a brief look at chronic kidney disease[J].Therapeutic Apheresis and Dialysis,2015,19(5):436-440.
[24]Shiba T,Kawakami K,Sasaki T,et al.Effects of intestinal bacteria-derived p-cresyl sulfate on Th1-type immune response in vivo and in vitro[J].Toxicology and Applied Pharmacology,2014,274(2):191-199.
[25]Neirynck N,Vanholder R,Schepers E,et al.An update on uremic toxins[J].International Urology and Nephrology,2013,45(1):139-150.
[26]Adesso S,Popolo A,Bianco G,et al.The uremic toxin indoxyl sulphate enhances macrophage response to LPS[J].PLoS One,2013,8(9):76-78.
[27]Ichii O,Otsuka-Kanazawa S,Nakamura T,et al.Podocyte injury caused by indoxyl sulfate,a uremic toxin and aryl-hydrocarbon receptor ligand[J].PLoS One,2014,9(9):e108448.
[28]Kanitsoraphan C,Rattanawong P,Charoensri S,et al.Trimethylamine N-oxide and risk of cardiovascular disease and mortality[J].Current Nutrition Reports,2018,7(4):207-213.
[29]Tang WH,Wang ZN,Kennedy DJ,et al.Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease[J].Circulation Research,2015,116(3):448-455.
[30]裴明,杨洪涛.从肠道微生态看中医肾病学的发展机遇[J].中华中医药杂志,2019,34(6):2336-2341.
[31]孔凡华,成泽东.肠道菌群失调的中医病机探讨[J].江西中医药大学学报,2016,28(6):6-7,13.
[32]李佳秀,戴恩来.基于肠道微生态干预慢性肾脏病[J].中医临床研究,2019,11(20):9-11.
[33]吉春兰,卓若君,吴禹池,等.基于肠道微生态探索“补脾益肾”法治疗慢性肾脏病的新思路[J].世界科学技术-中医药现代化,2017,19(7):1192-1198.
[34]杨晓安,潘娅,陈亚丽.肠道菌群对心血管疾病和肾脏的影响[J].中国循环杂志,2019,34(6):621-624.
[35]Lew QLJ,Jafar TH,Koh HWL,et al.Red meat intake and risk of ESRD[J].Journal of the American Society of Nephrology,2017,28(1):304-312.
[36]Kandouz S,Mohamed AS,Zheng YS,et al.Reduced protein bound uraemic toxins in vegetarian kidney failure patients treated by haemodiafiltration[J].Hemodialysis International,2016,20(4):610-617.
[37]Salmean YA,Segal MS,Langkamp-Henken B,et al.Foods with added fiber lower serum creatinine levels in patients with chronic kidney disease[J].Journal of Renal Nutrition,2013,23(2):e29-e32.
[38]Lu L,Huang YF,Wang MQ,et al.Dietary fiber intake is associated with chronic kidney disease (CKD) progression and cardiovascular risk,but not protein nutritional status,in adults with CKD[J].Asia Pac J Clin Nutr,2017,26(4):598-605.
[39]Vaziri ND,Liu SM,Lau WL,et al.High amylose resistant starch diet ameliorates oxidative stress,inflammation,and progression of chronic kidney disease[J].PLoS One,2014,9(12):e114881.
[40]Andrade-Oliveira V,Amano MT,Correa-Costa M,et al.Gut bacteria products prevent AKI induced by ischemia-reperfusion[J].Journal of the American Society of Nephrology:JASN,2015,26(8):1877-1888.
[41]Wang IK,Wu YY,Yang YF,et al.The effect of probiotics on serum levels of cytokine and endotoxin in peritoneal dialysis patients:a randomised,double-blind,placebo-controlled trial[J].Beneficial Microbes,2015,6(4):423-430.
[42]蒋红利,魏萌,刘华,等.益生菌对尿毒症大鼠肠道紧密连接和免疫功能调控的影响[J].临床医学研究与实践,2016,1(2):1-4,8.
[43]Miranda Alatriste PV,Urbina Arronte R,Gómez Espinosa CO,et al.Effect of probiotics on human blood urea levels in patients with chronic renal failure[J].Nutricion Hospitalaria,2014,29(3):582-590.
[44]Sueyoshi M,Fukunaga M,Mei M,et al.Effects of lactulose on renal function and gut microbiota in adenine-induced chronic kidney disease rats[J].Clinical and Experimental Nephrology,2019,23(7):908-919.
[45]Vaziri ND,Yuan J,Khazaeli M,et al.Oral activated charcoal adsorbent (AST-120) ameliorates chronic kidney disease-induced intestinal epithelial barrier disruption[J].American Journal of Nephrology,2013,37(6):518-525.
[46]Sato E,Saigusa D,Mishima E,et al.Impact of the oral adsorbent AST-120 on organ-specific accumulation of uremic toxins:LC-MS/MS and MS imaging techniques[J].Toxins(Basel),2017,10(1):E19.
[47]Mishima E,Fukuda S,Shima H,et al.Alteration of the intestinal environment by lubiprostone is associated with amelioration of adenine-induced CKD[J].Journal of the American Society of Nephrology:JASN,2015,26(8):1787-1794.
[48]姜东京,张丽,曹雨诞,等.肠道菌群在中药研究中的应用[J].中国中药杂志,2016,41(17):3218-3225.
[49]孙必强,周英,刘卫东,等.不同剂型七味白术散对肠道菌群失调小鼠肠黏膜和血清TNF-α,IL-6的影响[J].中国实验方剂学杂志,2016,22(4):95-100.
[50]唐华羽,李玉芝,李长德,等.四君子汤总多糖对小鼠肠道菌群及免疫功能的影响[J].陕西中医,2016,37(12):1688-1691.
[51]涂玥,孙伟,万毅刚,等.大黄附子汤调控JNK/Bcl-2信号通路而改善尿酸性肾病肾小管/间质损伤的机制[J].中华中医药杂志,2013,28(5):1351-1356,1636.
[52]贺海东,胡屏,孙蔚倩,等.固本泻浊方经结肠透析对慢性肾脏病患者微炎症状态的影响[J].中国中西医结合肾病杂志,2017,18(5):428-430.
[53]Zhou YL,Xu HM,Huang HL,et al.Are there potential applications of fecal microbiota transplantation beyond intestinal disorders?[J].BioMed Research International,2019,20(19):34,69,75.
[54]Wang ZN,Roberts AB,Buffa JA,et al.Non-lethal inhibition of gut microbial trimethylamine production for the treatment of atherosclerosis[J].Cell,2015,163(7):1585-1595.
[55]Nanto-Hara F,Kanemitsu Y,Fukuda S,et al.The guanylate cyclase C agonist linaclotide ameliorates the gut-cardio-renal axis in an adenine-induced mouse model of chronic kidney disease[J].Nephrology Dialysis Transplantation,2020,35(2):250-264.
[56]陈翀,孙伟.基于肠肾轴概念从肾-肺-大肠轴谈孙伟教授治疗慢性肾脏病的经验[J].西部中医药,2019,32(5):74-77.

相似文献/References:

[1]吴张浩1 王竹2 王志勇2.孙万森教授祛风通络法在肾病治疗中应用思路浅谈[J].陕西中医药大学学报,2019,(06):021.[doi:10.13424/j.cnki.jsctcm.2019.06.005]

备注/Memo

备注/Memo:
基金项目:辽宁省教育厅青年育苗计划项目(L202030)
更新日期/Last Update: 2022-05-30